

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY. DOCKET NO. PC25530A SERIAL NO. 10/720,600

APPLICANT Paul S. Changelian, et al.

FILING DATE November 24, 2003 GROUP 1624

U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
VB	US 3 0 3 7 9 8 0	6/5/62	Hitchings, et al.	260	256.4	
	US 5 2 7 2 1 4 7	12/21/93	Bell, et al.	514	234.2	
	US 5 3 8 9 5 0 9	2/14/95	Maskasky	430	567	
	US 5 4 9 6 9 4 6	3/5/96	Akimoto, et al.	544	321	
	US 5 6 8 6 4 5 7	11/11/97	Traxler, et al.	514	258	
	US 6 0 8 0 7 4 7	6/27/00	Uckun, et al.	514	259	
	US 6 1 3 6 5 9 5	10/24/00	Ihle, et al.	435	320.1	
	US 6 1 8 0 6 3 6	1/30/01	Traxler, et al.	514	258	
	US 6 1 8 7 5 5 2	2/13/01	Roberds, et al.	435	7.93	
	US 6 3 1 0 0 6 3	10/30/01	Ge, et al.	514	234.5	
	US 6 6 1 0 8 4 7	8/26/03	Blumenkopf, et al.	544	280	
	US 6 6 2 7 7 5 4	9/30/03	Blumenkopf, et al.	544	280	
	US 6 6 3 5 7 6 2	10/21/03	Blumenkopf, et al.	544	280	
	US 6 6 9 6 5 6 7	2/24/04	Blumenkopf, et al.	544	280	
	US 6 8 9 0 9 2 9	5/10/05	Blumenkopf, et al.	514	258	
	US 6 9 5 6 0 4 1	10/18/05	Blumenkopf, et al.	544	280	
	US 6 9 6 2 9 9 3	11/8/05	Blumenkopf, et al.	544	280	
	US 6 9 6 5 0 2 7	11/15/05	Flanagan, et al.	544	280	
	US 7 0 7 9 2 0 8	7/18/06	Kim, et al.	349	119	
W	US 7 0 9 1 2 0 8	8/15/06	Blumenkopf, et al.	514	259.1	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO
W EP 0 3 3 4 6 3 6	9/27/89	European	C07D	487/04	
EP 0 6 8 2 0 2 7	10/15/97	European	C07D	487/04	
EP 0 7 9 5 5 5 6	9/17/97	European	C07D	487/04	
W GB 0 9 1 5 3 0 3	1/9/63	Great Britain	C07D		




INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)						ATTY. DOCKET NO. PC25530A				SERIAL NO. 10/720,600			
						APPLICANT Paul S. Changelian, et al.							
						FILING DATE November 24, 2003				GROUP 1624			

W	WO	9	5	1	9	7	7	4	7/27/95	International	A61K	31/505		
	WO	9	6	4	0	1	4	2	12/19/98	International	A61K	31/505		
	WO	9	7	0	2	2	6	2	1/23/97	International	C07D	401/12		
	WO	9	7	0	2	2	6	6	1/23/97	International	C07D	487/04		
	WO	9	7	1	3	7	7	1	4/17/97	International	C07D	471/04		
	WO	9	7	1	8	2	1	2	5/22/97	International	C07D	473/34		
	WO	9	7	2	7	1	9	9	7/31/97	International	C07D	487/04		
	WO	9	7	2	8	1	6	1	8/7/97	International	C07D	487/04		
	WO	9	7	3	2	8	7	9	9/12/97	International	C07D	487/0		
	WO	9	7	4	9	7	0	6	12/31/97	International	C07D	487/04		
	WO	9	8	0	2	4	3	7	1/22/98	International	C07D	471/04		
	WO	9	8	0	2	4	3	8	7/13/96	International	C07D	471/04		
	WO	9	8	0	7	7	2	6	2/26/98	International	C07D	487/04		
	WO	9	8	2	3	6	1	3	6/4/98	International	C07D	471/04		
	WO	9	8	3	3	7	9	8	8/6/98	International	C07D	471/00		
	WO	9	9	5	1	5	9	9	10/14/99	International	C07D	471/04		
	WO	9	9	6	1	4	2	8	12/2/99	International	C07D	239/94		
	WO	9	9	6	5	9	0	8	12/23/99	International	C07D	487/04		
	WO	9	9	6	5	9	0	9	12/23/99	International	C07D	487/04		
	WO	0	0	0	0	2	0	2	1/16/00	International	A61K	31/517		
	WO	0	0	1	0	9	8	1	3/2/00	International	C07D	239/94		
	WO	0	0	1	7	2	0	3	3/30/00	International	C07D	487/04		
	WO	0	1	4	2	2	4	6	6/14/01	International	A61K	487/04		
W	WO	0	2	0	0	6	6	1	1/3/02	International	C07D	487/04		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
W			Aringer, et al., <u>Life Sciences</u> , "Janus Kinases and Their Role in Growth and Disease", Vol. 64, No. 24, pages 2173-2186 (1999)											
W			Baird, A.M., et al., <u>J. Leukocyte Biology</u> , "T Cell Development and Activation in JAK-3-Deficient Mice", Vol. 63, pages 669-672 (1998)											
W			Candotti, F., et al., <u>Springer Semin. Immunopathology</u> , "Severe Combined Immune Deficiencies due to Defects in the Common											

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC25530A	SERIAL NO. 10/720,600
			APPLICANT Paul S. Changelian, et al.	
			FILING DATE November 24, 2003	GROUP 1624
M			y chain-JAK3 Signaling Pathway", Vol. 19, pages 401-415 (1998)	
			Chen, E., et al., <u>Transplantation Proceedings</u> , "Advances in Cytokine Signaling: The Role of JAKs and STATs", Vol. 31, pgs. 1482 - 1487 (1999)	
			Eynon, E.E., et al., <u>Journal of Interferon and Cytokine Research</u> , "Disruption of Cytokine Signaling in Lymphoid Development: Unique Contributions of the Common Cytokine Gamma Chain and the JAK3 Kinase", Vol. 16, pgs. 667-684 (1996)	
			Ghosh, S., et al., <u>Acta Crystallogr. C: Crystal. Structure Commun.</u> , "4-[(3-Bromo-4-hydroxyphenyl)amino]6,7-dimethoxyquinazolin-1-ium Chloride Methanol Solvate and 4-[(3-hydroxyphenyl)amino]6,7-dimethoxy-1-quinazolinium Chloride", Vol. C57, pages 76-78 (2001)	
			Hanke, J.H., et al., <u>Inflammation Research</u> , "Role of Tyrosine Kinases in Lymphocyte Activation: Targets for Drug Intervention", Vol. 44, pgs. 357-371 (1995)	
			Ihle, J.N., <u>Advance Immunology</u> , "The Janus Protein Tyrosine Kinase Family and Its Role in Cytokine Signaling", Vol. 60, page 1-35 (1995)	
			Ihle, J.N., <u>Semin. Immunology</u> , "The Janus Protein Tyrosine Kinases in Hematopoietic Cytokine Signaling", Vol. 7, page 247 (1995)	
			Kirken, R.A., et al., <u>Cytokine</u> , "Activation of JAK3, but not JAK1, is Critical for IL-2-Induced Proliferation and Stat 5 Recruitment by a CooH-Terminal Region of IL-2 Receptor β -Chain", Vol. 7, pgs. 689-700 (1995)	
			Leonard, W.J., et al., <u>Annual Review of Immunology</u> , "JAKS and STATS: Biological Implications", Vol. 16, pgs. 293-322 (1998)	
			Li, X.C., et al., <u>Journal of Immunology</u> , "Blocking the Common γ -Chain of Cytokine Receptors Induces T Cell Apoptosis and Long-term Islet Allograft Survival", Vol. 164, pages 1193-1199 (2000)	
			Liu, K.D., et al., <u>Current Opinion of Immunology</u> , "JAK/STAT Signaling By Cytokine Receptors", Vol. 10, pages 271-278 (1998)	
			Malaviya, R., et al., <u>J. Pharmacol. Exp. Ther.</u> , "Treatment of Allergic Asthma by Targeting Janus Kinase 3-Dependent Leukotriene Synthesis in Mast Cells with 4-[(3-hydroxyphenyl)amino]6,7-dimethoxyquinazoline (WHI-P97)", Vol. 295, page 912 (2000)	
			Malaviya, R., et al., <u>Biochemistry Biophysical Research Community</u> , "Genetic and Biochemical Evidence for a Critical Role of Janus Kinase (JAK)-3 in Mast Cell-Mediated Type 1 Hypersensitivity Reactions", Vol. 257, pgs. 807-813 (1999)	
			Malaviya, R., et al., <u>Journal of Biological Chemistry</u> , "Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and Anaphylaxis", Vol. 274(38), pgs. 27028-27038 (1999)	
			Malabarba, M.G., et al., <u>Journal of Biological Chemistry</u> , "Activation of JAK3, but not JAK1, is Critical to Interleukin-4(IL4) Stimulated Proliferation and Requires a Membrane-Proximal Region of IL4 Receptor α ", Vol. 270(16), pgs. 9630-9637 (1995)	
			Moriggi, R., et al., <u>Immunity</u> , "Stat5 Activation is Uniquely Associated with Cytokine Signaling in Peripheral T Cells", Vol. 11, pgs. 225-230 (1995)	
			Musso, T., et al., <u>Journal of Experimental Medicine</u> , "Regulation of JAK3 Expression in Human Monocytes: Phosphorylation in Response to Interleukins 2, 4, and 7", Vol. 181, pages 1425-1431 (1995)	
			Nelson, B.H., et al., <u>Proceedings of National Academy of Science USA</u> , "Requirement for an Initial Signal from the Membrane-Proximal Region of the Interleukin 2 Receptor γ chain for Janus Kinase Activation Leading to T Cell Proliferation", Vol. 94, pgs. 1878-1883 (1997)	
			Notarangelo, L.D., et al., <u>Progressive Immunodeficiency</u> , "Severe Combined Immune Deficiency due to Defects of the JAK3 Tyrosine Kinase", Vol. 6, pgs. 61-68 (1996)	
M			Oakes, S.A., et al., <u>Immunity</u> , "Signaling via IL-2 and IL-4-JAK3-Deficient Severe Combined Immunodeficiency Lymphocytes: JAK3-Dependent and Independent Pathways", Vol. 5, pgs. 605-615 (1996)	

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY. DOCKET NO. PC25530A	SERIAL NO. 10/720,600
				APPLICANT Paul S. Changelian, et al.	
				FILING DATE November 24, 2003	GROUP 1624
Vm				O'Shea, J.J., et al., <u>Nature</u> , "Phosphorylation and Activation of the JAK-3 Janus Kinase in Response to Interleukin-2", Vol. 370(14), pages 151-153 (1994)	
				Russell, S.M., et al., <u>Science</u> , "Interaction of IL-2R β and γ_c Chains with JAK1 and JAK3: Implications for XSCID and XCID", Vol. 266, pages 1042-1045 (1994)	
				Shouda, et al., <u>The Journal of Clinical Investigation</u> , "Induction of the Cytokine Signal Regulator SOCS3/CIS3 as a Therapeutic Strategy for Treating Inflammatory Arthritis", Vol. 108(12) pages 1781-1788 (2001)	
				Sudbeck, E.A., et al., <u>Clinical Cancer Research</u> , "Structure-based Design of Specific Inhibitors of Janus Kinase 3 Apoptosis-Inducing Antileukemic Agents", Vol. 5, pages 1569-1582 (1999)	
				Sudbeck, E.A., et al., <u>IDrugs</u> , "Recent Advances in JAK3 Kinase Inhibitors", Vol. 2(10), pages 1026-1030 (1999)	
				Sudbeck, E.A., et al., <u>Acta Crystallogr., Sect C: Cryst. Struct. Commun.</u> , "An Inhibitor of Janus Kinase 3: 4-(4-hydroxyphenyl)amino-6,7-dimethoxyquinazolin-1-ium chloride", Vol. C56, pages 1282-1283 (2000)	
				Thomis, D.C., et al., <u>The Journal of Immunology</u> , "The JAK Family Tyrosine Kinase JAK3 is Required for IL-2 Synthesis by Naive/Resting CD4 ⁺ T Cells", Vol. 163, pages 5411-5417 (1999)	
				Thomis, D.C., et al., <u>Journal of Experimental Medicine</u> , "Peripheral Expression of JAK3 is Required to Maintain T Lymphocyte Function", Vol. 185(2), pages 197-206 (1997)	
				Traxler, et al., <u>Experimental Opinion Therapeutic Pat.</u> , "Protein Tyrosine Kinase Inhibitors in Cancer Treatment", Vol. 7(6), pages 571-588 (1997)	
				Traxler, et al., <u>J. Med. Chem.</u> , "4-(Phenylamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase", Vol. 39, pages 2285-2292 (1996)	
				Trieu, V.N., et al., <u>Biochemistry Biophysical Research Communications</u> , "A Specific Inhibitor of Janus Kinase-3 Increases Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis", Vol. 267, pages 22-25 (2000)	
				Uckun, F.M., et al., <u>Clinical Cancer Research</u> , "In Vivo Toxicity and Pharmacokinetic Features of the Janus Kinase 3 Inhibitor WHI-P131 [40(4'-Hydroxyphenyl)-Amino-6,7-Dimethoxyquinazoline]", Vol. 5, pages 2954-2962 (1999)	
				Wang, L.H., et al., <u>Journal of Immunology</u> , "JAK3, STAT, and MAPK Signaling Pathways as Novel Molecular Targets for the Tyrophostin AG-490 Regulation of IL-2-Mediated T Cell Response", Vol. 162, page 3897 (1999)	
				US Serial No. 09/335,121 filed June 17, 1999 (PC10285A) Todd A. Blumenkopf	
				US Publication No. 2003-0073719 (Publication Date: 4/17/03) (PC23066A) Mark E. Flanagan	
				US Publication No. 2004-0229923 (Publication Date: 11/18/04) (PC23066B) Glenn E. Wilcox	
				US Publication No. 2004-0058922 (Publication Date: 3/25/04) (PC10209B) Todd A. Blumenkopf	
				US Publication No. 2004-0116449 (Publication Date: 6/17/04) (PC25530A) Paul Changelian	
				US Publication No. 2005-0197349 (Publication Date: 9/8/05) (PC11027C) Todd A. Blumenkopf	
				US Publication No. 2005-0171128 (Publication Date: 8/4/05) (PC10285D) Todd A. Blumenkopf	
				US Publication No. 2005-0159433 (Publication Date: 7/21/05) (PC32063A) Paul Changelian	
VP				US Publication No. 2005-0159434 (Publication Date: 7/21/05) (PC32261B) Mark E. Flanagan	

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC25530A	SERIAL NO. 10/720,600
	APPLICANT Paul S. Changelian, et al.	
	FILING DATE November 24, 2003	GROUP 1624
	US Publication No. 2006-0241131 (Publication date: 10/26/06) (PC10609D) Todd A. Blumenkopf	
EXAMINER 	DATE CONSIDERED 	
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>		

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE